Phase 1/2 Study of LYL273 in Relapsed or Refractory mCRC Initiated
A Phase 1/2 open-label study is underway to evaluate LYL273 in patients with relapsed or refractory metastatic colorectal cancer.
Therapeutic Area
Therapeutic area intelligence for mCRC with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.